A systematic literature review on the use of platelet transfusions in patients with thrombocytopenia

References

• Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver International: Official Journal of the International Association for the Study of the Liver. 2017;37(6):778–793.
   PubMed Web of Science ®Google Scholar
• Smock KJ, Perkins SL. Thrombocytopenia: an update. Int J Lab Hematol. 2014;36(3):269–278.
   PubMed Web of Science ®Google Scholar
• Williamson DR, Lesur O, Tétrault JP, et al. Thrombocytopenia in the critically ill: prevalence, incidence, risk factors, and clinical outcomes. Can J Anaesth. 2013;60(7):641–651.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol. 2009;46(1 Suppl 2):S26–S32.
   PubMed Web of Science ®Google Scholar
• Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48(6):1000–1007.
   PubMed Web of Science ®Google Scholar
• Provan D, Newland AC. Current management of primary immune thrombocytopenia. Adv Ther. 2015;32(10):875–887.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015;29(4):282–294.
   PubMed Web of Science ®Google Scholar
• Liou SY, Stephens JM, Carpiuc KT, et al. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig. 2007;27(6):381–396.
   PubMed Web of Science ®Google Scholar
• Freireich EJ. Origins of platelet transfusion therapy. Transfus Med Rev. 2011;25(3):252–256.
   PubMed Web of Science ®Google Scholar
• Schiffer CA, Bohlke K, Delaney M, et al. Platelet transfusion for patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2018;36(3):283–299.
   PubMed Web of Science ®Google Scholar
• Estcourt LJ, Birchall J, Allard S, et al. Guidelines for the use of platelet transfusions. Br J Haematol. 2017;176(3):365–394.
   PubMed Web of Science ®Google Scholar
• Squires JE. Indications for platelet transfusion in patients with thrombocytopenia. Blood Transfus. 2015;13(2):221–226.
   PubMed Web of Science ®Google Scholar
• Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162(3):205–213.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Blood transfusion. NICE guideline [NG24]; 2015 [cited 2019 June 20]. Available from: https://www.nice.org.uk/guidance/ng24.
   Google Scholar
• Spiess BD, Royston D, Levy JH, et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion. 2004;44(8):1143–1148.
   PubMed Web of Science ®Google Scholar
• Bilgin YM, van de Watering LM, Versteegh MI, et al. Postoperative complications associated with transfusion of platelets and plasma in cardiac surgery. Transfusion. 2011;51(12):2603–2610.
   PubMed Web of Science ®Google Scholar
• Aubron C, Flint AW, Bailey M, et al. Is platelet transfusion associated with hospital-acquired infections in critically ill patients? Crit Care. 2017;21(1):2.
   PubMed Web of Science ®Google Scholar
• Tinegate H, Birchall J, Gray A, et al. Guideline on the investigation and management of acute transfusion reactions. Prepared by the BCSH blood transfusion task force. Br J Haematol. 2012;159(2):143–153.
   PubMed Web of Science ®Google Scholar
• Katus MC, Szczepiorkowski ZM, Dumont LJ, et al. Safety of platelet transfusion: past, present and future. Vox Sang. 2014;107(2):103–113.
   PubMed Web of Science ®Google Scholar
• Valsami S, Dimitroulis D, Gialeraki A, et al. Current trends in platelet transfusions practice: the role of ABO-RhD and human leukocyte antigen incompatibility. Asian J Transfus Sci. 2015;9(2):117–123.
   PubMedGoogle Scholar
• Goel R, Ness PM, Takemoto CM, et al. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood. 2015;125(9):1470–1476.
   PubMed Web of Science ®Google Scholar
• Raval JS, Mazepa MA, Russell SL, et al. Passive reporting greatly underestimates the rate of transfusion-associated circulatory overload after platelet transfusion. Vox Sang. 2015;108(4):387–392.
   PubMed Web of Science ®Google Scholar
• Stolla M, Refaai MA, Heal JM, et al. Platelet transfusion – the new immunology of an old therapy. Front Immunol. 2015;6:28.
   PubMed Web of Science ®Google Scholar
• Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. Transfusion. 2012;52(1):160–165.
   PubMed Web of Science ®Google Scholar
• Killick SB, Carter C, Culligan D, et al. Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol. 2014;164(4):503–525.
   PubMed Web of Science ®Google Scholar
• Khan Assir MZ, Kamran U, Ahmad HI, et al. Effectiveness of platelet transfusion in dengue fever: a randomized controlled trial. Transfus Med Hemother. 2013;40(5):362–368.
   PubMed Web of Science ®Google Scholar
• Estcourt LJ, Birchall J, Lowe D, et al. Platelet transfusions in haematology patients: are we using them appropriately? Vox Sang. 2012;103(4):284–293.
   PubMed Web of Science ®Google Scholar
• Garner S. Inherent variation in donor platelet function: potential clinical implications. Transfus Med. 2013;23(Suppl 2):4.
   Google Scholar
• Hess JR. Conventional blood banking and blood component storage regulation: opportunities for improvement. Blood Transfus. 2010;8(Suppl 3):s9–s15.
   PubMed Web of Science ®Google Scholar
• Maurer-Spurej E, Chipperfield K. Past and future approaches to assess the quality of platelets for transfusion. Transfus Med Rev. 2007;21(4):295–306.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for industry. Determining donor eligibility for autologous donors of blood and blood components intended solely for autologous use – compliance policy. 2016 [cited 2019 June 20]. Available from: https://www.fda.gov/media/99325/download.
   Google Scholar
• US Food and Drug Administration. Guidance for industry. Use of Sterile Connecting Devices in Blood Bank Practices; Department of Health and Human Services. 2000 [cited 2019 June 20]. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm062885.pdf.
   Google Scholar
• US Food and Drug Administration. Pre storage leukocyte reduction of whole blood and blood components intended for transfusion. Department of Health and Human Services. 2012 [cited 2019 June 20]. Available from: https://www.fda.gov/media/84460/download.
   Google Scholar
• Robinson S, Harris A, Atkinson S, et al. The administration of blood components: a British society for haematology guideline. Transfus Med. 2018;28(1):3–21.
   PubMed Web of Science ®Google Scholar
• Ellingson KD, Sapiano MRP, Haass KA, et al. Continued decline in blood collection and transfusion in the United States-2015. Transfusion. 2017;57(Suppl 2):1588–1598.
   PubMed Web of Science ®Google Scholar
• Estcourt LJ. Why has demand for platelet components increased? A review. Transfus Med. 2014;24(5):260–268.
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Nissman D, et al. AHRQ technical reviews. Criteria for distinguishing effectiveness from efficacy trials in systematic reviews. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006.
   Google Scholar
• Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. March 2011 [cited 2019 June 20]. Available from: https://handbook-5-1.cochrane.org/.
   Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Penson DF, Krishnaswami S, Jules A, et al. AHRQ comparative effectiveness reviews. Evaluation and treatment of cryptorchidism. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012.
   Google Scholar
• Ang DC, Marinescu L, Kuriyan M. Physician compliance with platelet usage criteria. Arch Pathol Lab Med. 2008;132(8):1321–1324.
   PubMed Web of Science ®Google Scholar
• Blumberg N, Gettings KF, Turner C, et al. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. Transfusion. 2006;46(10):1813–1821.
   PubMed Web of Science ®Google Scholar
• Chandran A, Warner M, Schenck L, et al. Prophylactic platelet transfusion is not associated with decreased ICU red blood cell requirements. Crit Care. 2015;43(12):97.
   Web of Science ®Google Scholar
• Saleh MN, Fisher M, Grotzinger KM. Analysis of the impact and burden of illness of adult chronic ITP in the US. Curr Med Res Opin. 2009;25(12):2961–2969.
   PubMed Web of Science ®Google Scholar
• Warner MA, Woodrum D, Hanson A, et al. Preprocedural platelet transfusion for patients with thrombocytopenia undergoing interventional radiology procedures is not associated with reduced bleeding complications. Transfusion. 2017;57(4):890–898.
   PubMed Web of Science ®Google Scholar
• Wu Y, Aravind S, Ranganathan G, et al. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000–2007. Clin Ther. 2009;31(Pt 2):2416–2432.
   PubMed Web of Science ®Google Scholar
• Andrade-Campos MM, Montes-Limón AE, Soro-Alcubierre G, et al. Patients older than 65 years with non-hodgkin lymphoma are suitable for treatment with (90)Yttrium-ibritumumab tiuxetan: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2015;15(8):464–471.
   PubMed Web of Science ®Google Scholar
• Greeno E, McCullough J, Weisdorf D. Platelet utilization and the transfusion trigger: a prospective analysis. Transfusion. 2007;47(2):201–205.
   PubMed Web of Science ®Google Scholar
• Habr B, Charpentier J, Champigneulle B, et al. Platelet transfusions in cancer patients with hypoproliferative thrombocytopenia in the intensive care unit. Ann Intensive Care. 2015;5(1):46.
   PubMed Web of Science ®Google Scholar
• Wandt H, Schaefer-Eckart K, Frank M, et al. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006;37(4):387–392.
   PubMed Web of Science ®Google Scholar
• Benson AB, Burton JRJ, Austin GL, et al. Differential effects of plasma and red blood cell transfusions on acute lung injury and infection risk following liver transplantation. Liver Transpl. 2011;17(2):149–158.
   PubMed Web of Science ®Google Scholar
• Pillarisetti J, Patel P, Duthuluru S, et al. Cardiac catheterization in patients with end-stage liver disease: safety and outcomes. Catheter Cardiovasc Interv. 2011;77(1):45–48.
   PubMed Web of Science ®Google Scholar
• Giannini EG, Greco A, Marenco S, et al. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol. 2010;8(10):899–902. quiz e109.
   PubMed Web of Science ®Google Scholar
• Napolitano G, Iacobellis A, Merla A, et al. Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia. Eur J Intern Med. 2017;38:79–82.
   PubMed Web of Science ®Google Scholar
• Terrault N, Kuter DJ, Izumi N, et al. Superiority of avatrombopag to placebo in increasing platelet counts in patients with chronic liver disease-associated thrombocytopenia undergoing scheduled procedures: results from 2, Phase 3 randomized studies. Blood. 2017;130(Suppl 1):18.
   Google Scholar
• Snyder E, McCullough J, Slichter SJ, et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion. 2005;45(12):1864–1875.
   PubMed Web of Science ®Google Scholar
• Murphy S, Snyder E, Cable R, et al. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion. 2006;46(1):24–33.
   PubMed Web of Science ®Google Scholar
• Basu P, Shah N, Krishnaswamy N, et al. Assessment of tissue tumor necrosis factor alfa (TTNF-α) as a novel marker for latent celiac disease. J Gastroenterol Hepatol. 2012;27(Suppl 5):152.
   Google Scholar
• Stanworth SJ, Estcourt LJ, Llewelyn CA, et al. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion. 2014;54(10):2385–2393.
   PubMed Web of Science ®Google Scholar
• Hess JR, Trachtenberg FL, Assmann SF, et al. Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial. Vox Sang. 2016;111(3):281–291.
   PubMed Web of Science ®Google Scholar
• McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood. 2004;104(5):1534–1541.
   PubMed Web of Science ®Google Scholar
• Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362(7):600–613.
   PubMed Web of Science ®Google Scholar
• Basu P, Shah NJ, Farhat S, et al. Single use of romiplostim thrombopoietin analogue (TPO) in severe thrombocytopaenia for outpatient percutaneous liver biopsy in patients with chronic liver disease (CLD): a randomised double blinded prospective clinical pilot trial. Gut. 2012;61(Suppl 2):A187–A188.
   Web of Science ®Google Scholar
• Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013;368(19):1771–1780.
   PubMed Web of Science ®Google Scholar
• Lye DC, Archuleta S, Syed-Omar SF, et al. Prophylactic platelet transfusion plus supportive care versus supportive care alone in adults with dengue and thrombocytopenia: a multicentre, open-label, randomised, superiority trial. Lancet. 2017;389(10079):1611–1618.
   PubMed Web of Science ®Google Scholar
• Veelo DP, Vlaar AP, Dongelmans DA, et al. Correction of subclinical coagulation disorders before percutaneous dilatational tracheotomy. Blood Transfus. 2012;10(2):213–220.
   PubMed Web of Science ®Google Scholar
• Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012;380(9850):1309–1316.
   PubMed Web of Science ®Google Scholar
• Stanca CM, Montazem AH, Lawal A, et al. Intranasal desmopressin versus blood transfusion in cirrhotic patients with coagulopathy undergoing dental extraction: a randomized controlled trial. J Oral Maxillofac Surg. 2010;68(1):138–143.
   PubMed Web of Science ®Google Scholar
• Lu FQ, Zhao DW, Peng Y. Clinical study on the effect of reducing prophylactic platelet transfusion dose on bleeding in stable thrombocytopenia patients. Vox Sang. 2013;105:262.
   Web of Science ®Google Scholar
• Tinmouth A, Tannock IF, Crump M, et al. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion. 2004;44(12):1711–1719.
   PubMed Web of Science ®Google Scholar
• Sensebé L, Giraudeau B, Bardiaux L, et al. The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. Blood. 2005;105(2):862–864.
   PubMed Web of Science ®Google Scholar
• Heddle NM, Cook RJ, Tinmouth A, et al. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood. 2009;113(7):1564–1573.
   PubMed Web of Science ®Google Scholar
• Klumpp TR, Herman JH, Gaughan JP, et al. Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial. Transfusion. 1999;39(7):674–681.
   PubMed Web of Science ®Google Scholar
• Johansson PI, Simonsen A, Ostrowski SR, et al. TEG as a surrogate marker for the haemostatic function of PRT treated platelets in thrombocytopenic patients. Transfusion (Paris). 2012;52:67A.
   Web of Science ®Google Scholar
• Johansson PI, Simonsen AC, Brown PN, et al. A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia. Transfusion. 2013;53(9):2043–2052.
   PubMed Web of Science ®Google Scholar
• Garban F, Guyard A, Labussière H, et al. Comparison of the hemostatic efficacy of pathogen-reduced platelets vs untreated platelets in patients with thrombocytopenia and malignant hematologic diseases: a randomized clinical trial. JAMA Oncol. 2018;4(4):468–475.
   PubMed Web of Science ®Google Scholar
• de Wildt-Eggen J, Nauta S, Schrijver JG, et al. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion. 2000;40(4):398–403.
   PubMed Web of Science ®Google Scholar
• Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion. 2010;50(11):2362–2375.
   PubMed Web of Science ®Google Scholar
• Kerkhoffs JL, van Putten WL, Novotny VM, et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol. 2010;150(2):209–217.
   PubMed Web of Science ®Google Scholar
• Lozano M, Knutson F, Tardivel R, et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol. 2011;153(3):393–401.
   PubMed Web of Science ®Google Scholar
• Janetzko K, Cazenave JP, Klüter H, et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion. 2005;45(9):1443–1452.
   PubMed Web of Science ®Google Scholar
• Simonsen AC, Johansson PI, Conlan MG, et al. Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Transfusion. 2006;46(3):424–433.
   PubMed Web of Science ®Google Scholar
• van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood. 2003;101(6):2426–2433.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Kavanagh JJ, Freedman RS, et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet. 2002;359(9324):2145–2152.
   PubMed Web of Science ®Google Scholar
• Zhu M, Xu W, Wang BL, et al. Hemostatic function and transfusion efficacy of apheresis platelet concentrates treated with gamma irradiation in use for thrombocytopenic patients. Transfus Med Hemother. 2014;41(3):189–196.
   PubMed Web of Science ®Google Scholar
• Diedrich B, Ringdén O, Watz E, et al. A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients. Vox Sang. 2009;97(3):254–259.
   PubMed Web of Science ®Google Scholar
• Heddle NM, Klama L, Meyer R, et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion. 1999;39(3):231–238.
   PubMed Web of Science ®Google Scholar
• Heddle NM, Blajchman MA, Meyer RM, et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion. 2002;42(5):556–566.
   PubMed Web of Science ®Google Scholar
• Van Der Meer PF, Ypma PF, van Geloven N, et al. Hemostatic efficacy of pathogen-inactivated buffy coat-derived platelet concentrates in hemato-oncological patients: outcomes of the prepares trial. Blood. 2017;130(Suppl 1):704.
   Google Scholar
• Afdhal N, Duggal A, Ochiai T, et al. Platelet response to lusutrombopag, a thrombopoietin receptor agonist, in patients with chronic liver disease and thrombocytopenia undergoing non-emergency invasive procedures: results from a Phase 3 randomized, double-blind, placebo-controlled study. Blood. 2017;130(Suppl 1):291.
   Google Scholar
• Izumi N, Osaki Y, Yamamoto K, et al. A Phase 3, randomized, double-blind, placebo-controlled study of lusutrombopag for thrombocytopenia in patients with chronic liver disease undergoing elective invasive procedures in Japan (L-PLUS 1). Hepatology. 2015;62(6):1397A–1398A.
   Web of Science ®Google Scholar
• Tateishi R, Seike M, Kudo M, et al. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation. J Gastroenterol. 2019;54(2):171–181.
   PubMed Web of Science ®Google Scholar
• Afdhal NH, Giannini EG, Tayyab G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012;367(8):716–724.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Wong RS, Verma A, et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol. 2015;2(10):e417–e426.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Greenberg PL, et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010;116(17):3163–3170.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Hamlin PA, Gabrilove J, et al. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Oncol. 2007;18(11):1842–1850.
   PubMed Web of Science ®Google Scholar
• Noris P, Schlegel N, Klersy C, et al. Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. Haematologica. 2014;99(8):1387–1394.
   PubMed Web of Science ®Google Scholar
• Arnold DM, Crowther MA, Cook RJ, et al. Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses. Transfusion. 2006;46(8):1286–1291.
   PubMed Web of Science ®Google Scholar
• Ning S, Barty R, Liu Y, et al. Platelet transfusion practices in the ICU: data from a large transfusion registry. Chest. 2016;150(3):516–523.
   PubMed Web of Science ®Google Scholar
• Krishna SG, Rao BB, Thirumurthi S, et al. Safety of endoscopic interventions in patients with thrombocytopenia. Gastrointest Endosc. 2014;80(3):425–434.
   PubMed Web of Science ®Google Scholar
• Meehan KR, Matias CO, Rathore SS, et al. Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol. 2000;64(4):251–256.
   PubMed Web of Science ®Google Scholar
• Charbonnier A, Raba M, Ladaique P, et al. Preventive versus curative platelet transfusion strategies in the treatment of acute myeloid leukemia patients: a comparative study. Blood. 2014;124(21):4288.
   Web of Science ®Google Scholar
• Wandt H, Frank M, Ehninger G, et al. Safety and cost effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91(10):3601–3606.
   PubMed Web of Science ®Google Scholar
• Swisher KK, Terrell DR, Vesely SK, et al. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion. 2009;49(5):873–887.
   PubMed Web of Science ®Google Scholar
• Samuelson Bannow BT, Walter RB, Gernsheimer TB, et al. Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes. J Thromb Thrombolysis. 2017;44(4):442–447.
   PubMed Web of Science ®Google Scholar
• Spahr JE, Rodgers GM. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am J Hematol. 2008;83(2):122–125.
   PubMed Web of Science ®Google Scholar
• Toor AA, Choo SY, Little JA. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Bone Marrow Transplant. 2000;26(3):315–320.
   PubMed Web of Science ®Google Scholar
• Ypma PF, Kerkhoffs JL, van Hilten JA, et al. The observation of bleeding complications in haemato-oncological patients: stringent watching, relevant reporting. Transfus Med. 2012;22(6):426–431.
   PubMed Web of Science ®Google Scholar
• Li J, Han B, Li H, et al. Association of coagulopathy with the risk of bleeding after invasive procedures in liver cirrhosis. Saudi J Gastroenterol. 2018;24(4):220–227.
   PubMed Web of Science ®Google Scholar
• Park JA, Kim HD, An J, et al. Platelet replacement is not necessary before endoscopic variceal band ligation in patients with cirrhosis and severe thrombocytopenia. J Gastroenterol and Hepatol (Australia). 2015;30(Suppl 4):362.
   Google Scholar
• Arnold DM, Ning S, Barty R, et al. The effect of platelet transfusion on death in the intensive care unit. Blood. 2016;128(22):3850.
   Web of Science ®Google Scholar
• Beneke J, Sartison A, Kielstein JT, et al. Clinical and laboratory consequences of platelet transfusion in Shiga toxin-mediated hemolytic uremic syndrome. Transfus Med Rev. 2017;31(1):51–55.
   PubMed Web of Science ®Google Scholar
• Chen X, Peng B, Cai Y, et al. Laparoscopic splenectomy for patients with immune thrombocytopenia and very low platelet count: is platelet transfusion necessary? J Surg Res. 2011;170(2):e225–e232.
   PubMed Web of Science ®Google Scholar
• Duffy SM, Coyle TE. Platelet transfusions and bleeding complications associated with plasma exchange catheter placement in patients with presumed thrombotic thrombocytopenic purpura. J Clin Apher. 2013;28(5):356–358.
   PubMed Web of Science ®Google Scholar
• Goel R, Ness PM, Takemoto C, et al. Platelet transfusion practices in platelet consumptive disorders and associated in-hospital complications and mortality: nationally representative data from 2007–2011. Transfusion (Paris). 2014;2014(54):33A.
   Google Scholar
• Guerrero WR, Gonzales NR, Sekar P, et al. Variability in the use of platelet transfusion in patients with intracerebral hemorrhage: observations from the ethnic/racial variations of intracerebral hemorrhage study. J Stroke Cerebrovasc Dis. 2017;26(9):1974–1980.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Konkle BA, Hamza TH, et al. Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia. Am J Hematol. 2017;92(8):730–738.
   PubMed Web of Science ®Google Scholar
• Lee TH, Wong JG, Leo YS, et al. Potential harm of prophylactic platelet transfusion in adult dengue patients. PLoS Negl Trop Dis. 2016;10(3):e0004576.
   PubMed Web of Science ®Google Scholar
• Lye DC, Lee VJ, Sun Y, et al. Lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in adults with acute uncomplicated dengue infection. Clin Infect Dis. 2009;48(9):1262–1265.
   PubMed Web of Science ®Google Scholar
• Makroo R, Chowdhry M, Nayak S, et al. Platelet transfusion in cases of TTP undergoing therapeutic plasma exchange: retrospective analysis of 5 years. Vox Sang. 2014;107(Suppl 1):211.
   Google Scholar
• Otrock ZK, Liu C, Grossman BJ. Platelet transfusion in thrombotic thrombocytopenic purpura. Vox Sang. 2015;109(2):168–172.
   PubMed Web of Science ®Google Scholar
• Sethi SM, Khalil A, Naseem Khan MR, et al. Clinical outcomes of prophylactic platelet transfusion in patients with dengue: a retrospective study of patients at a tertiary care hospital in Karachi. J Pak Med Assoc. 2017;67(9):1374–1378.
   PubMed Web of Science ®Google Scholar
• Tran L, Goel R, Krishnamurti L. Platelet transfusions in patients with immune thrombocytopenic purpura (ITP) – evaluation of the current nationwide inpatient hospital practices. Blood. 2010;116(21):3809.
   PubMed Web of Science ®Google Scholar
• Warner MA, Jia Q, Clifford L, et al. Preoperative platelet transfusions and perioperative red blood cell requirements in patients with thrombocytopenia undergoing noncardiac surgery. Transfusion. 2016;56(3):682–690.
   PubMed Web of Science ®Google Scholar
• Yoshii Y, Matsumoto M, Norio K, et al. Introduction of a quick assay for ADAMTS13 activity improved a survival of acquired TTP patients who received platelet transfusions. Blood. 2014;124(21):4209.
   Web of Science ®Google Scholar
• Wallace MJ, Narvios A, Lichtiger B, et al. Transjugular liver biopsy in patients with hematologic malignancy and severe thrombocytopenia. J Vasc Interv Radiol. 2003;14(3):323–327.
   PubMed Web of Science ®Google Scholar
• Schmidt AE, Henrichs KF, Kirkley SA, et al. Prophylactic preprocedure platelet transfusion is associated with increased risk of thrombosis and mortality. Am J Clin Pathol. 2018;149(1):87–94.
   Web of Science ®Google Scholar
• Keulers AR, Kiesow L, Mahnken AH. Port implantation in patients with severe thrombocytopenia is safe with interventional radiology. Cardiovasc Intervent Radiol. 2018;41(1):80–86.
   PubMed Web of Science ®Google Scholar
• Fillmore WJ, Leavitt BD, Arce K. Dental extraction in the thrombocytopenic patient is safe and complications are easily managed. J Oral Maxillofac Surg. 2013;71(10):1647–1652.
   PubMed Web of Science ®Google Scholar
• Engele LJ, Straat M, van Rooijen IHM, et al. Transfusion of platelets, but not of red blood cells, is independently associated with nosocomial infections in the critically ill. Ann Intensive Care. 2016;6(1):67.
   PubMed Web of Science ®Google Scholar
• Vetter TR, Adhami LF, Porterfield JRJ, et al. Perceptions about blood transfusion: a survey of surgical patients and their anesthesiologists and surgeons. Anesth Analg. 2014;118(6):1301–1308.
   PubMed Web of Science ®Google Scholar
• Cheung D, Lieberman L, Lin Y, et al. Consent for blood transfusion: do patients understand the risks and benefits? Transfus Med. 2014;24(5):269–273.
   PubMed Web of Science ®Google Scholar
• Barnett CL, Mladsi D, Vredenburg M, et al. Cost estimate of platelet transfusion in the United States for patients with chronic liver disease and associated thrombocytopenia undergoing elective procedures. J Med Econ. 2018;21(8):827–834.
   PubMed Web of Science ®Google Scholar
• Bell CE, Botteman MF, Gao X, et al. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther. 2003;25(9):2464–2486.
   PubMed Web of Science ®Google Scholar
• Berger K, Bauer M, Schopohl D, et al. Model calculations to quantify clinical and economic effects of pathogen inactivation in platelet concentrates. Onkologie. 2013;36(1-2):53–59.
   PubMedGoogle Scholar
• Birchall J, Karakantza M, Moss R, et al. A quality improvement project which initiated a change in practice and several million pounds worth of savings to the NHS. Br J Haematol. 2017;176(Suppl 1):133–134.
   Google Scholar
• Brown RSJ. Review article: a pharmacoeconomic analysis of thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther. 2007;26(Suppl 1):41–48.
   PubMed Web of Science ®Google Scholar
• Callow CR, Swindell R, Randall W, et al. The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. Br J Haematol. 2002;118(2):677–682.
   PubMed Web of Science ®Google Scholar
• Campbell HE, Estcourt LJ, Stokes EA, et al. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion. 2014;54(10):2394–2403.
   PubMed Web of Science ®Google Scholar
• Cantor SB, Elting LS, Hudson DVJ, et al. Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer. 2003;97(12):3099–3106.
   PubMed Web of Science ®Google Scholar
• Elting LS, Cantor SB, Martin CG, et al. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer. 2003;97(6):1541–1550.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Requirements for blood and blood components intended for transfusion or for further manufacturing use. Department of Health and Human Services. 2006 [cited 2019 June 20]. Available from: https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/EconomicAnalyses/UCM449783.pdf.
   Google Scholar
• Forsythe A, Bhor M, Roy A, et al. Economic burden of immune thrombocytopenia (ITP) in patients receiving eltrombopag (EPAG) and romiplostim (ROMI): real world evidence from 26 US institutions. Value Health. 2017;20(9):A552.
   Web of Science ®Google Scholar
• Jimenez-Marco T, Bautista-Gili A, Girona-Llobera E. Reducing platelet outdating cost, an important advantage of pathogen-reduction technology. Transfusion (Paris). 2014;54:87A.
   Web of Science ®Google Scholar
• Juskewitch JE, Norgan AP, De Goey SR, et al. How do I … manage the platelet transfusion-refractory patient? Transfusion. 2017;57(12):2828–2835.
   PubMed Web of Science ®Google Scholar
• Lin J, Zhang X, Li X, et al. Cost of bleeding-related episodes in adult patients with primary immune thrombocytopenia: a population-based retrospective cohort study of administrative claims data for commercial payers in the United States. Clin Ther. 2017;39(3):603–609.e1.
   PubMed Web of Science ®Google Scholar
• Paessens B, Ihbe-Heffinger A, von Schilling C, et al. Blood component use and associated costs after standard dose chemotherapy—a prospective analysis of routine hospital care in lymphoproliferative disorders and NSCLC in Germany. Support Care Cancer. 2012;20(5):1011–1021.
   PubMed Web of Science ®Google Scholar
• Riley W, Smalley B, Pulkrabek S, et al. Using lean techniques to define the platelet (PLT) transfusion process and cost-effectiveness to evaluate PLT dose transfusion strategies. Transfusion. 2012;52(9):1957–1967.
   PubMed Web of Science ®Google Scholar
• Staginnus U, Corash L. Economics of pathogen inactivation technology for platelet concentrates in Japan. Int J Hematol. 2004;80(4):317–324.
   PubMed Web of Science ®Google Scholar
• Stokes EA, Wordsworth S, Staves J, et al. Accurate costs of blood transfusion: a microcosting of administering blood products in the United Kingdom National Health Service. Transfusion. 2018;58(4):846–853.
   PubMed Web of Science ®Google Scholar
• Whitaker B. The 2011 National blood collection and utilization survey report. 2011 [cited 2019 June 20]. Available from: http://www.aabb.org/research/hemovigilance/bloodsurvey/Documents/11-nbcus-report.pdf.
   Google Scholar
• Whitaker BI, Rajbhandary S, Kleinman S, et al. Trends in United States blood collection and transfusion: results from the 2013 AABB blood collection, utilization, and patient blood management survey. Transfusion. 2016;56(9):2173–2183.
   PubMed Web of Science ®Google Scholar
• Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001;19(4):1137–1146.
   PubMed Web of Science ®Google Scholar
• Goodnough LT, DiPersio JF. Issues in the management of cancer-related thrombocytopenia. Oncology (Williston Park). 2002;16(11):1558–1567. discussion 70, 72–74.
   PubMed Web of Science ®Google Scholar
• Habibi A, Esfandbod M, Ghafari MH, et al. Platelet kinetics after slow versus standard transfusions: a pilot study. Ups J Med Sci. 2011;116(3):212–215.
   PubMed Web of Science ®Google Scholar
• Khalafallah AA, Al-Barzan AM, Camino A, et al. An open-labelled, randomized cross-over study of the effect of electromechanical pumps versus conventional gravity flow on platelet transfusion in adult haematology patients. Transfus Med Hemother. 2013;40(1):22–26.
   Web of Science ®Google Scholar
• MacLennan S, Harding K, Llewelyn C, et al. A randomized noninferiority crossover trial of corrected count increments and bleeding in thrombocytopenic hematology patients receiving 2- to 5- versus 6- or 7-day-stored platelets. Transfusion. 2015;55(8):1856–1865. quiz 5.
   PubMed Web of Science ®Google Scholar
• Slichter SJ, Raife TJ, Davis K, et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion. 2006;46(5):731–740.
   PubMed Web of Science ®Google Scholar
• Akpunonu P, Luu S, Brudevold J, et al. Prevalence and characteristics of thrombocytopenia after North American rattlesnake envenomations reported to a statewide poison control system. Clin Toxicol. 2013;52(7):739.
   Web of Science ®Google Scholar
• Al Zaabi M, Clark S, Gomez K, et al. Assessing risk of bleeding in thrombocytopenic patients requiring platelet transfusion prior to invasive procedures. Haematologica. 2014;99(Suppl 1):199.
   Google Scholar
• Alikiaii B, Hashemi S, Manteghi F. Evaluation of platelet elevation after injection in patients over 40 years of age admitted hospital; a retrospective study. Journal of Isfahan Medical School. 2017;35(451):1438–1443.
   Google Scholar
• Al-Samkari H, Marshall AL, Goodarzi K, et al. Romiplostim for the management of perioperative thrombocytopenia. Br J Haematol. 2018;182(1):106–113.
   PubMed Web of Science ®Google Scholar
• Antun AG, Gleason S, Arellano M, et al. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. Cancer. 2013;119(21):3784–3787.
   PubMed Web of Science ®Google Scholar
• Bhat A, Chowdappa V, Masamatti SS. Effectiveness of pooled platelet transfusion in concordant and discordant groups among dengue patients. J Clin Diagn Res. 2016;10(7):EC21–EC24.
   PubMed Web of Science ®Google Scholar
• Chan G, DiVenuti G, Miller K. Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome. Am J Hematol. 2002;71(3):166–171.
   PubMed Web of Science ®Google Scholar
• Chaoui D, Chakroun T, Robert F, et al. Reticulated platelets: a reliable measure to reduce prophylactic platelet transfusions after intensive chemotherapy. Transfusion. 2005;45(5):766–772.
   PubMed Web of Science ®Google Scholar
• Chern JJ, Tsung AJ, Humphries W, et al. Clinical outcome of leukemia patients with intracranial hemorrhage. Clinical article. J Neurosurg. 2011;115(2):268–272.
   PubMed Web of Science ®Google Scholar
• Chien JL, Hsu LW, Tsai JT, et al. Retrospective study of platelet transfusion refractoriness in Tzu Chi hospital in central Taiwan. Vox Sang. 2014;107(Suppl 1):228.
   Google Scholar
• Cirasino L, Robino AM, Cattaneo M, et al. Appropriate hospital management of adult immune thrombocytopenic purpura patients in major Italian institutions in 2000–2002: a retrospective analysis. Blood Coagul Fibrinolysis. 2010;21(1):77–84.
   PubMed Web of Science ®Google Scholar
• Davaasambuu B, Gritsaev S. The effectiveness of platelets transfusions in patients with de novo acute myeloid leukemia (AML) during induction chemotherapy (IC). Haematologica. 2013;98(Suppl 1):193.
   PubMed Web of Science ®Google Scholar
• Delaitre B, Champault G, Barrat C, et al. Laparoscopic splenectomy for hematologic diseases. Study of 275 cases. Ann Chir. 2000;125(6):522–529.
   PubMedGoogle Scholar
• Dzierba AL, Roberts R, Muir J, et al. Severe thrombocytopenia in adults with severe acute respiratory distress syndrome: impact of extracorporeal membrane oxygenation use. ASAIO J. 2016;62(6):710–714.
   PubMed Web of Science ®Google Scholar
• Eder AF, Dy BA, Perez JM, et al. The residual risk of transfusion-related acute lung injury at the American Red Cross (2008–2011): limitations of a predominantly male-donor plasma mitigation strategy. Transfusion. 2013;53(7):1442–1449.
   PubMed Web of Science ®Google Scholar
• Feliciano J, Yang Y, Lu M, et al. Burden of cytopenias among myelofibrosis patients. J Clin Oncol. 2016;34(Suppl 15):e18260.
   Web of Science ®Google Scholar
• Frigaa I, Mahnaoui H, Rached B, et al. Assessment of efficacy platelet transfusion in acute leukemia. Vox Sang. 2015;109(Suppl 2):88.
   Google Scholar
• Fujimura K, Harada Y, Fujimoto T, et al. Nationwide study of idiopathic thrombocytopenic purpura in pregnant women and the clinical influence on neonates. Int J Hematol. 2002;75(4):426–433.
   PubMed Web of Science ®Google Scholar
• Gerber DE, Grossman SA, Zeltzman M, et al. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro-Oncology. 2007;9(1):47–52.
   PubMed Web of Science ®Google Scholar
• Guerrero WR, Gonzales NR, Sekar P, et al. Predictors of platelet transfusion in patients with intracerebral hemorrhage. Stroke. 2014;45(Suppl 1):AWP235.
   Google Scholar
• Hashiguchi Y, Fukuda T, Ichimura T, et al. Chemotherapy-induced thrombocytopenia and clinical bleeding in patients with gynecologic malignancy. Eur J Gynaecol Oncol. 2015;36(2):168–173.
   PubMed Web of Science ®Google Scholar
• Hitron A, Steinke D, Sutphin S, et al. Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors. J Oncol Pharm Pract. 2011;17(4):312–319.
   PubMedGoogle Scholar
• Hussein MA, Fletcher R, Long TJ, et al. Transfusing platelets 2 h after the completion of amphotericin-B decreases its detrimental effect on transfused platelet recovery and survival. Transfus Med. 1998;8(1):43–47.
   PubMed Web of Science ®Google Scholar
• Jones RM, de Lloyd L, Kealaher EJ, et al. Platelet count and transfusion requirements during moderate or severe postpartum haemorrhage. Anaesthesia. 2016;71(6):648–656.
   PubMed Web of Science ®Google Scholar
• Jubelirer SJ, Mousa L, Reddy U, et al. Coronary artery bypass grafting (CABG) in patients with immune thrombocytopenia (ITP): a community hospital experience and review of the literature. W V Med J. 2011;107(6):10–14.
   PubMedGoogle Scholar
• Kander T, Tanaka KA, Norström E, et al. The effect and duration of prophylactic platelet transfusions before insertion of a central venous catheter in patients with bone marrow failure evaluated with point-of-care methods and flow cytometry. Anesth Analg. 2014;119(4):882–890.
   PubMed Web of Science ®Google Scholar
• Kluge S, Meyer A, Kühnelt P, et al. Percutaneous tracheostomy is safe in patients with severe thrombocytopenia. Chest. 2004;126(2):547–551.
   PubMed Web of Science ®Google Scholar
• Kwon C, Forsythe A, Roy A, et al. Health care resource use (HCRU) due to bleeding related episodes (BRE) in patients with immune thrombocytopenic purpura (ITP) receiving eltrombopag (EPAG), romiplostim (ROMI), or rituximab (RITUX): real world evidence (RWE) from 27 US institutions. Value Health. 2017;20(9):A558.
   Web of Science ®Google Scholar
• Lawrence JB, Yomtovian RA, Hammons T, et al. Lowering the prophylactic platelet transfusion threshold: a prospective analysis. Leuk Lymphoma. 2001;41(1-2):67–76.
   PubMed Web of Science ®Google Scholar
• Levin MD, de Veld JC, van der Holt B, et al. Immune and nonimmune causes of low recovery from leukodepleted platelet transfusions: a prospective study. Ann Hematol. 2003;82(6):357–362.
   PubMed Web of Science ®Google Scholar
• Limkemann AJ, Tessier JM, Cooney L, et al. Increased incidence of blood product transfusions among transplant patients treated with linezolid therapy: a retrospective, cohort study. Am Surg. 2015;81(11):E385–E387.
   PubMed Web of Science ®Google Scholar
• Mahévas M, Gerfaud-Valentin M, Moulis G, et al. A multicenter, case-control study evaluating the characteristics and outcome of ITP patients refractory to, rituximab, splenectomy and both TPO receptor agonists. Blood. 2015;126(23):3460.
   Web of Science ®Google Scholar
• Mathias SD, Bussel JB, George JN, et al. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes. 2007;5:11.
   PubMed Web of Science ®Google Scholar
• McDonald MJ, Herman JH. Platelet transfusion response in thrombotic thrombocytopenic purpura (TTP). Transfusion (Paris). 2012;52(Suppl 3):193A–194A.
   Google Scholar
• Mohd Hayat MZ, Hassan MN, Ahmed SA. Clinical factors that influencing platelet increment after platelet transfusion in the thrombocytopenic patients in Hospital USM. Malays J Pathol. 2016;38(2):200.
   Google Scholar
• Moulis G, Comont T, Germain J, et al. Clinical epidemiology and first-line treatment in immune thrombocytopenia adults. Results of the CARMEN prospective cohort. Blood. 2015;126(23):3473.
   Web of Science ®Google Scholar
• Nandagopal L, Veeraputhiran M, Jain T, et al. Bronchoscopy can be done safely in patients with thrombocytopenia. Transfusion. 2016;56(2):344–348.
   PubMed Web of Science ®Google Scholar
• Neukirchen J, Blum S, Kuendgen A, et al. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. Eur J Haematol. 2009;83(5):477–482.
   PubMed Web of Science ®Google Scholar
• Nevo S, Fuller AK, Hartley E, et al. Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 × 10(9) and 20 × 10(9) per L. Transfusion. 2007;47(5):801–812.
   PubMed Web of Science ®Google Scholar
• Nevo S, Fuller AK, Zahurak ML, et al. Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 × 10(9) or 20 × 10(9) per L. Transfusion. 2007;47(9):1700–1709.
   PubMed Web of Science ®Google Scholar
• Nevo S, Enger C, Hartley E, et al. Acute bleeding and thrombocytopenia after bone marrow transplantation. Bone Marrow Transplant. 2001;27(1):65–72.
   PubMed Web of Science ®Google Scholar
• Niwa T, Suzuki A, Sakakibara S, et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther. 2009;31(10):2126–2133.
   PubMed Web of Science ®Google Scholar
• Norol F, Bierling P, Roudot-Thoraval F, et al. Platelet transfusion: a dose-response study. Blood. 1998;92(4):1448–1453.
   PubMed Web of Science ®Google Scholar
• Palo R, Capraro L, Hanhela R, et al. Platelet transfusions in adult patients with particular reference to patients undergoing surgery. Transfus Med. 2010;20(1):30–37.
   PubMed Web of Science ®Google Scholar
• Poordad F, Theodore D, Sullivan J, et al. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia. J Med Econ. 2011;14(2):194–206.
   PubMedGoogle Scholar
• Pugmire DE. Early treatment with rhIL-11 in heavily pretreated patients with gynecologic cancer. Commun Oncol. 2006;3(6):357–362.
   Google Scholar
• Qureshi H, Lowe D, Dobson P, et al. National comparative audit of the use of platelet transfusions in the UK. Transfus Clin Biol. 2007;14(6):509–513.
   PubMed Web of Science ®Google Scholar
• Rabon A, Fisher J, Mazur J, et al. Incidence and risk factors for linezolid-associated thrombocytopenia in critically ill patients. Crit Care Med. 2018;46(1):319.
   Web of Science ®Google Scholar
• Ramos GP, Binder M, Hampel P, et al. Outcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia. Gastrointest Endosc. 2018;88(1):55–61.
   PubMed Web of Science ®Google Scholar
• Ramos GP, Al-Bawardy B, Braga Neto MB, et al. Gastrointestinal bleeding in severe thrombocytopenia: efficacy and safety of endoscopy. Gastrointest Endosc. 2016;83(5 Suppl):AB455.
   Web of Science ®Google Scholar
• Ranucci M, Baryshnikova E, for the Surgical and Clinical Outcome Research Score Group. The interaction between preoperative platelet count and function and its relationship with postoperative bleeding in cardiac surgery. Platelets. 2017;28(8):794–798.
   PubMed Web of Science ®Google Scholar
• Rao MP, Boralessa H, Morgan C, et al. Blood component use in critically ill patients. Anaesthesia. 2002;57(6):530–534.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Besalduch J, Michel M, et al. Treatment practices in adults with chronic immune thrombocytopenia – a European perspective. Eur J Haematol. 2010;84(2):160–168.
   PubMed Web of Science ®Google Scholar
• Roubinian N, Escobar G, Gardner M, et al. Epidemology of platelet transfusion in hospitalized patients: data from an integrated health care delivery system. Transfusion (Paris). 2016;56(Suppl 4):168A–169A.
   Google Scholar
• Samuelson BT, Garcia DA, Gernsheimer TB, et al. Central venous catheter (CVC)-related thrombosis (CRT) in leukemia patients with severe thrombocytopenia: a retrospective analysis. Am J Hematol. 2016;91:E368.
   Web of Science ®Google Scholar
• Sanz MÁ, Jarque I, Yuste VJ, et al. Sequence of treatment in immune thrombocytopenia (ITP) patients: results of a medical record review from eight hospitals in Spain. Value Health. 2010;13(7):A472.
   Google Scholar
• Schuh J, Carreira J, Gaspar C, et al. Posttransfusion platelet response in hematological inpatients. Haematol. 2013;98(Suppl 1):729.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Narang M, Komrokji RS, et al. Therapeutic response to azacitidine (AZA) in patients with secondary myelodysplastic syndromes (sMDS) enrolled in the AVIDA registry. Blood. 2010;116(21):2931.
   Web of Science ®Google Scholar
• Shreenivas AV, Coltoff A, Afshar S, et al. A single institution experience of performing bloodless transplant in a Jehovah’s Witness patient based on data gathered from review of transfusion support requirements in autologous stem cell transplantation for the treatment of 60 myeloma patients. Biol Blood Marrow Transplant. 2018;24(14):S143.
   Google Scholar
• Singh PP, Timucin T, Nagorney DM, et al. Splenectomy for massive splenomegaly associated with myelofibrosis: outcomes from 63 patients at Mayo clinic. Blood. 2012;120(21):2848.
   Web of Science ®Google Scholar
• Tada K, Ohta M, Saga K, et al. Long-term outcomes of laparoscopic versus open splenectomy for immune thrombocytopenia. Surg Today. 2018;48(2):180–185.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Takesue Y, Nakajima K, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother. 2011;17(3):382–387.
   PubMed Web of Science ®Google Scholar
• Tessier JM, Puzio T, Young A, et al. Thrombocytopenia associated with linezolid therapy in solid organ transplant recipients: a retrospective cohort study. Surg Infect (Larchmt). 2015;16(4):361–367.
   PubMed Web of Science ®Google Scholar
• Tsukune Y, Komatsu N. Management of adult chronic immune thrombocytopenia in Japan: patient and hematologist perspectives from a multi-center cross-sectional questionnaire survey. Intern Med. 2016;55(17):2379–2385.
   PubMed Web of Science ®Google Scholar
• Vecchio R, Cacciola E, Lipari G, et al. Laparoscopic splenectomy reduces the need for platelet transfusion in patients with idiopathic thrombocytopenic purpura. JSLS. 2005;9(4):415–418.
   PubMedGoogle Scholar
• Vigil-De Gracia P. Addition of platelet transfusions to corticosteroids does not increase the recovery of severe HELLP syndrome. Eur J Obstet Gynecol Reprod Biol. 2006;128(1-2):194–198.
   PubMed Web of Science ®Google Scholar
• Vijenthira A, Premkumar D, Wells RA, et al. Rates of severe bleeding are low in patients with MDS and severe thrombocytopenia and may be mitigated by tranexamic acid. Blood. 2017;130(Suppl 1):1691.
   Google Scholar
• Virgili A, Arqueros C, Payán S, et al. Retrospective analyses of the patterns of platelet transfusions in patients with solid tumors treated with chemotherapy. Eur J Cancer. 2015;51(Suppl 3):S246.
   Web of Science ®Google Scholar
• Wang C, Smith BR, Ault KA, et al. Reticulated platelets predict platelet count recovery following chemotherapy. Transfusion. 2002;42(3):368–374.
   PubMed Web of Science ®Google Scholar
• Wu Z, Zhou J, Li J, et al. The feasibility of laparoscopic splenectomy for ITP patients without preoperative platelet transfusion. Hepatogastroenterology. 2012;59(113):81–85.
   PubMedGoogle Scholar
• Zahur-ur-Rehman A, Alam M. Platelet transfusion practice in a tertiary care hospital. J Coll Physicians Surg Pak. 2002;12(8):485–487.
   Google Scholar
• Zeidler K, Arn K, Senn O, et al. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. Transfusion. 2011;51(11):2269–2276.
   PubMed Web of Science ®Google Scholar
• Zhou L, Zhang LZ, Wang JY, et al. Perioperative safety analysis of transcatheter arterial chemoembolization for hepatocellular carcinoma patients with preprocedural leukopenia or thrombocytopenia. Mol Clin Oncol. 2017;7(3):435–442.
   PubMed Web of Science ®Google Scholar